ESR1 and neoplasm: While it has been highlighted that a relative change in PIK3CA allele frequency after 15 days strongly predicted PFS on palbociclib and fulvestrant, on the other hand, ESR1 dynamics offered limited information on the long-term clinical outcome, probably due to early divergent response of tumor subclones to treatment and the more gradual onset of new ESR1 mutations (21).